Brigham and Women's Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (21)

2024

  1. Developmental or Procedural Vena Cava Interruption and Venous Thromboembolism: A Review

    Seminars in Thrombosis and Hemostasis, Vol. 50, Núm. 6, pp. 851-865

  2. Fibrinolytic Agents in Thromboembolic Diseases: Historical Perspectives and Approved Indications

    Seminars in Thrombosis and Hemostasis, Vol. 50, Núm. 5, pp. 773-789

2023

  1. 36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE

    Thrombosis Research, Vol. 222, pp. 31-39

  2. A second update on mapping the human genetic architecture of COVID-19

    Nature

  3. Cancer-Associated Thrombosis: Trends in Clinical Features, Treatment, and Outcomes From 2001 to 2020

    JACC: CardioOncology, Vol. 5, Núm. 6, pp. 758-772

  4. Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials

    Journal of the American College of Cardiology, Vol. 81, Núm. 1, pp. 16-30

  5. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  6. Sex-Related Differences in Patient Characteristics, Risk Factors, and Symptomatology in Older Adults with Pulmonary Embolism: Findings from the SERIOUS-PE Study

    Seminars in Thrombosis and Hemostasis, Vol. 49, Núm. 7, pp. 725-735

2022

  1. Detailed stratified GWAS analysis for severe COVID-19 in four European populations

    Human Molecular Genetics, Vol. 31, Núm. 23, pp. 3945-3966

  2. Developing Validated Tools to Identify Pulmonary Embolism in Electronic Databases: Rationale and Design of the PE-EHR+ Study

    Thrombosis and Haemostasis, Vol. 123, Núm. 6, pp. 649-662

  3. Sex Differences in PrEsentation, Risk Factors, Drug and Interventional Therapies, and OUtcomes of Elderly PatientS with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study

    Thrombosis Research, Vol. 214, pp. 122-131

  4. Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment

    Contemporary Clinical Trials, Vol. 115

2021

  1. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

2020

  1. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

    Journal of the American College of Cardiology, Vol. 75, Núm. 23, pp. 2950-2973

  2. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research

    Thrombosis and Haemostasis, Vol. 120, Núm. 7, pp. 1004-1024

2019

  1. Pulmonary embolism hospitalization, readmission, and mortality rates in US older adults, 1999-2015

    JAMA - Journal of the American Medical Association

  2. Use of Prophylaxis for Prevention of Venous Thromboembolism in Patients with Isolated Foot or Ankle Surgery: A Systematic Review and Meta-Analysis

    Thrombosis and Haemostasis, Vol. 19, Núm. 10, pp. 1686-1694

2017

  1. Comparison of fatal or irreversible events with extended-duration betrixaban versus standard dose enoxaparin in acutely Ill medical patients: An APEX trial substudy

    Journal of the American Heart Association, Vol. 6, Núm. 7

2016

  1. Extended thromboprophylaxis with betrixaban in acutely ill medical patients

    New England Journal of Medicine, Vol. 375, Núm. 6, pp. 534-544

  2. Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: A pooled analysis of 926 patients

    Journal of Thrombosis and Haemostasis, Vol. 14, Núm. 1, pp. 105-113